Peritoneal damage by peritoneal dialysis solutions.
Continuous ambulatory peritoneal dialysis is a well-accepted treatment for end-stage renal disease, but its long-term success is limited. Peritoneal sclerosis is still one of the most important complications of long-term peritoneal dialysis and the low biocompatibility of peritoneal dialysis solutions plays a major role in the development of such sclerosis. In this review, we summarize recent experimental data about the biocompatibility of peritoneal dialysis solutions.
Ito
Takafumi
T
Section of Nephrology, Department of Internal Medicine, Faculty of Medicine, Shimane University, 85-1, Enya-cho, Izumo, 693-8501, Japan.
Yorioka
Noriaki
N
Department of Advanced Nephrology, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. nyorioka@hiroshima-u.ac.jp.
D015312:Hemodialysis Solutions / Q000009:adverse effects*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D010532:Peritoneal Diseases / Q000139:chemically induced* / Q000473:pathology; D010537:Peritoneum / Q000187:drug effects / Q000473:pathology; D012598:Sclerosis
D015312:Hemodialysis Solutions